Apixaban ( DrugBank: Apixaban )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
222	Primary nephrotic syndrome	1

222. Primary nephrotic syndrome

---

Clinical trials : 310 /  Drugs : 295 - (DrugBank : 117) / Drug target genes : 63 - Drug target pathways : 194

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-001212-29-DK (EUCTR)	26/08/2020	09/06/2020	Causes and prevention of thrombosis developed due to the kidney disease nephrotic syndrome	Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome	Nephrotic syndrome is defined as severe proteinuria (> 0.5 g / day), edema and hypoalbuminemia. It is conditioned by a defect in the kidney's glomerular filtration barrier, resulting in the loss of a large number of plasma proteins including coagulation factors and consequently a increased risk of thromboembolic complications. The most frequent cause of nephrotic syndrome is the renal disease membranous nephropathy, which is associated with the greatest risk of thromboembolic complications. MedDRA version: 21.1;Level: LLT;Classification code 10029167;Term: Nephrotic syndrome with lesion of membranous glomerulonephritis;System Organ Class: 100000004857 MedDRA version: 20.0;Classification code 10029165;Term: Nephrotic syndrome in diseases classified elsewhere;System Organ Class: 100000004857;Therapeutic area: Not possible to specify	Trade Name: Fragmin INN or Proposed INN: Dalteparin Other descriptive name: Dalteparin Trade Name: Eliquis INN or Proposed INN: Apixaban Other descriptive name: Apixaban	Aarhus University Hospital, Henrik Birn	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	70	Phase 1;Phase 2	Denmark